In Brief: Apixaban vs Rivaroxaban for Acute VTE
The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 103-103
DOI: 10.58347/tml.2026.1757f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.
Abstract (Originalsprache)
The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban (Xarelto, and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at least 3 months.1 The other DOACs (edoxaban [Savaysa] and dabigatran [Pradaxa, and generics]) are alternatives for long-term treatment, but they require prior treatment with low-molecular-weight heparin for ≥5 days.2 Until recently, no large randomized trial directly comparing the safety of apixaban and rivaroxaban for treatment of VTE was available.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). In Brief: Apixaban vs Rivaroxaban for Acute VTE. The Medical Letter on Drugs and Therapeutics, 68(1757), 103-103. https://doi.org/10.58347/tml.2026.1757f
Vancouver
In Brief: Apixaban vs Rivaroxaban for Acute VTE. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):103-103. doi:10.58347/tml.2026.1757f
BibTeX
@article{euvimed2026,
title = {In Brief: Apixaban vs Rivaroxaban for Acute VTE},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1757},
pages = {103--103},
doi = {10.58347/tml.2026.1757f}
}
EUVIMED